The NLRP3 inflammasome in acute myocardial infarction (Q45073088)

9 December 2017

The NLRP3 inflammasome in acute myocardial infarction (English)

1 reference

9 December 2017

myocardial infarction

1 reference

1 reference

Stefano Toldo

1

1 reference

9 December 2017

Antonio Abbate

series ordinal

2

1 reference

9 December 2017

language of work or name

English

0 references

publication date

16 November 2017

1 reference

Nature Reviews Cardiology

9 December 2017

1 reference

https://scigraph.springernature.com/pub.10.1038/nrcardio.2017.161

9 December 2017

0 references

cites work

Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Post-infarct cardiac rupture: recent insights on pathogenesis and therapeutic interventions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The inflammasome in myocardial injury and cardiac remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Mechanism of NLRP3 inflammasome activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Cathepsin B inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The role of mitochondria in reactive oxygen species metabolism and signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Role of the Mitochondrial Permeability Transition in Apoptotic and Necrotic Death After Ischemia / Reperfusion Injury to Hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

A role for mitochondria in NLRP3 inflammasome activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inflammasome and autophagy regulation - a two-way street

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Defective mitochondrial fission augments NLRP3 inflammasome activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Mitochondria are the powerhouses of immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Impaired autophagy contributes to adverse cardiac remodeling in acute myocardial infarction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Role of NLRP3 (cryopyrin) in acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

NLRP3 and downstream cytokine expression elevated in the monocytes of patients with coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

NLRP3 inflammasome as a novel player in myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Letter by Mezzaroma, et al regarding article, "NLRP3 inflammasome as a therapeutic target in myocardial infarction".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

NOD2 deficiency protects against cardiac remodeling after myocardial infarction in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Glyburide inhibits the Cryopyrin/Nalp3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

BAY 11-7082, a nuclear factor-κB inhibitor, reduces inflammation and apoptosis in a rat cardiac ischemia-reperfusion injury model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Colchicine--Update on mechanisms of action and therapeutic uses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Re. "NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective"

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Targeting interleukin-1 in heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Cutting edge: IL-1α is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Reduction of Myocardial Ischemia-Reperfusion Injury by Inhibiting Interleukin-1 Alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The protective role of interleukin-18 binding protein in a murine model of cardiac ischemia/reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1β induces a reversible cardiomyopathy in the mouse.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis: the role of NLRP3 inflammasome activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The heart on fire: inflammasome and cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Involvement of NLRP3 inflammasome in CVB3-induced viral myocarditis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Inflammatory markers in ST-elevation acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Low-dose colchicine for secondary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2017.161

The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.

31 March 2020

1 reference

12 December 2020

Mitochondrial function is required for extracellular ATP-induced NLRP3 inflammasome activation

1 reference

12 December 2020

Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways

1 reference

12 December 2020

Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).

1 reference

12 December 2020

10.1038/NRCARDIO.2017.161

Identifiers

DOI

1 reference

Dimensions Publication ID

9 December 2017

0 references

1 reference